Hydroxyprogesterone Caproate
Generic Details
Generic Name
Hydroxyprogesterone Caproate
Other Names
- Makena
- 17α-Hydroxyprogesterone hexanoate
Drug Class
- Progestin
- Synthetic Progestogen
Chemical Formula
C27H40O4
Molecular Weight
428.611 g/mol
Mechanism of Action
- Binds to progesterone receptors, reducing estrogen production and altering endometrial development.
Indications
- Prevention of preterm birth in pregnant women with a history of spontaneous preterm birth.
Common Dosage Forms
- Injection
Typical Dosage
- 250 mg intramuscularly once weekly
Pediatric Dosage
- Not established
Geriatric Dosage
- Consult healthcare provider for dosage adjustments
Side Effects
- Injection site reactions
- Nausea
- Vomiting
- Diarrhea
- Swelling
- Itching
- Dizziness
Contraindications
- Hypersensitivity to hydroxyprogesterone caproate or its components
- History of thrombosis
- Liver dysfunction
Pregnancy Category
- Category B - Animal reproduction studies have failed to demonstrate a risk to the fetus.
Lactation Safety
- Considered compatible with breastfeeding
Drug Interactions
- Avoid concomitant use with drugs that induce liver enzymes
- May enhance the effects of corticosteroids
Overdose Symptoms
- Excessive drowsiness
- Nausea
- Vomiting
- Irregular heartbeat
Antidote for Overdose
- Supportive care and symptom management
Storage Conditions
- Store in the original container at controlled room temperature (20-25°C)
Pharmacokinetics
- Absorption: Well absorbed after intramuscular injection
- Distribution: Protein-bound in plasma
- Metabolism: Hepatic metabolism
- Excretion: Primarily excreted in urine as metabolites
Precautions
- Monitor for signs of preterm labor during therapy
- Monitor liver function tests during treatment
Warnings
- Not for use to reduce the risk of preterm birth in women with multiple gestations
- Increased risk of thrombosis
Others
- Consider consultation with a healthcare provider before initiating therapy.